Physicians

Department / Division
Medicine / Medicine-Pulmonary

Address
DUMC 3278
Durham, NC 27710

Appointment Telephone
919-668-7630

Office Telephone
919-620-7306

Fax Telephone
919-471-5374

Training

• MD, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1991

Residency

• Internal Medicine, Duke University Medical Center, 1991-1993

Fellowship

• Rheumatology, Duke University Medical Center, 1993-1995
• Allergy and Immunology, Duke University Medical Center, 1995-1996

Other Training

• PhD, Immunology, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1991

Clinical Interests
Asthma, allergic rhinitis, immunotherapy, general allergy

Research Interests
Research Theme

The focus of my research is on human-based translational studies and therapeutic trials of novel agents for inflammatory and immunologic diseases. My group has experience in mechanistic studies of environmental exposure in airway diseases; genetic analysis and gene expression studies using microarrays; airway challenge and assessment of response in the upper and lower airway and periphery; and therapeutic trials of experimental agents in Phases I-IV. Areas of focus include:

Asthma and Allergic Diseases

Research interests in asthma and allergic diseases focus upon human studies investigating the response to environmental endotoxin exposure. Using airway challenge with lipopolysaccharide and well characterized allergens, we investigate the genetic regulation of immunologic and inflammatory responses in the lung and in the periphery. This work is performed in collaboration with investigators with expertise in bench science and computational biology. In addition I participate in a number of multi-center research projects related to experimental therapeutics and genetic susceptibility to asthma and allergic diseases.

Rheumatologic Diseases

My primary research focus in rheumatologic diseases is on experimental therapeutics in chronic gout. Gout is the most common inflammatory arthritis in men, and the prevalence of disease is increasing in the population. We have led Phase I through III studies of pegloticase (PEGylated uricase) in subjects with treatment failure gout. We have initiated a new line of investigation that focuses upon IL-1 inhibition in the treatment of inflammation in acute and chronic gout.

Duke Clinical Research Institute - Multicenter Clinical Trials

I serve as the Director of Rheumatology and Allergy Research at the Duke Clinical Research Institute, a large academic research organization with expertise in the coordination of multi-center clinical trials and registries. Our objective is to develop a diverse portfolio of research registries and clinical trials in rheumatic and immunologic disease led by investigators at Duke. Currently our group is involved in programs in pediatric lupus, systemic onset JIA, gout, rheumatoid arthritis, and scleroderma.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• American College of Rheumatology
• Ardea Biosciences, Inc.
• BioCryst Pharmaceuticals
• General Electric Company
• Novartis
• Nuon Therapeutics
• Pharmos Corporation
• Roche
• Savient Pharmaceuticals, Inc
• TCL Institute
• Takeda Pharmaceutical Co. Ltd.

Representative Publications
Hauswirth DW, Sundy JS, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Levesque MC. Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans. J Allergy Clin Immunol. 2008 Jul;122(1):101-6. (2008) Abstract

Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Allen AS, Sundy JS. Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults. J Allergy Clin Immunol. 2008 Feb;121(2):396-402.e3. (2008) Abstract

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z, . Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum. 2008 Sep;58(9):2882-91. (2008) Abstract

Sundy JS. Gout management: let's get it right this time. Arthritis Rheum. 2008 Nov 15;59(11):1535-7. (2008) Abstract

American Lung Association Asthma Clinical Research Centers (including JS Sundy). 2007. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 175(3): 235-42. (2007)

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007 Mar;56(3):1021-8. (2007) Abstract

Sundy JS, Hauswirth DW, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, Allgood S, McNair PD, Levesque MC. Smoking is associated with an age-related decline in exhaled nitric oxide. Eur Respir J. 2007 Oct 10. (2007) Abstract

Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007 Jun;9(3):258-64. (2007) Abstract

Webb BT, van den Oord E, Akkari A, Wilton S, Ly T, Duff R, Barnes KC, Carlsen K, Gerritsen J, Lenney W, Silverman M, Sly P, Sundy J, Tsanakas J, von Berg A, Whyte M, Blumenthal M, Vestbo J, Middleton L, Helms PJ, Anderson WH, Pillai SG. Quantitative linkage genome scan for atopy in a large collection of Caucasian families. Hum Genet. 2007 Mar;121(1):83-92. (2007) Abstract

Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12. (2006) Abstract

Pillai SG, Chiano MN, White NJ, Speer M, Barnes KC, Carlsen K, Gerritsen J, Helms P, Lenney W, Silverman M, Sly P, Sundy J, Tsanakas J, von Berg A, Whyte M, Varsani S, Skelding P, Hauser M, Vance J, Pericak-Vance M, Burns DK, Middleton LT, Brewster SR, Anderson WH, Riley JH. A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p. Eur J Hum Genet. 2006 Mar;14(3):307-16. (2006) Abstract

Schiffman SS, Studwell CE, Landerman LR, Berman K, Sundy JS. Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects. Environ Health Perspect. 2005 May;113(5):567-76. (2005) Abstract

Hauswirth DW, Sundy JS. Bioaerosols and innate immune responses in airway diseases. Curr Opin Allergy Clin Immunol. 2004 Oct;4(5):361-6. (2004) Abstract

McCrory DC, Williams JW, Dolor RJ, Gray RN, Kolimaga JT, Reed S, Sundy J, Witsell DL. Management of allergic rhinitis in the working-age population. Evid Rep Technol Assess (Summ). 2003 Jan;(67):1-4. (2003) Abstract

American Lung Association Asthma Clinical Research Centers (including JS Sundy). 2001. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 345(21): 1529-36. (2001)